These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Karagiannis A; Tziomalos K; Kakafika A; Florentin M; Athyros VG Nephrol Dial Transplant; 2007 Jan; 22(1):293. PubMed ID: 17018542 [No Abstract] [Full Text] [Related]
5. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Dupont A Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716 [No Abstract] [Full Text] [Related]
6. Spironolactone-induced gynaecomastia related to allergic reaction to "Darvon compound". Licata AA; Bartter FC Lancet; 1976 Oct; 2(7991):905. PubMed ID: 62134 [No Abstract] [Full Text] [Related]
7. Antialdosterones: incidence and prevention of sexual side effects. de Gasparo M; Whitebread SE; Preiswerk G; Jeunemaître X; Corvol P; Ménard J J Steroid Biochem; 1989 Jan; 32(1B):223-7. PubMed ID: 2913412 [TBL] [Abstract][Full Text] [Related]
8. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. Greenblatt DJ; Koch-Weser J JAMA; 1973 Jul; 225(1):40-3. PubMed ID: 4740303 [No Abstract] [Full Text] [Related]
9. Ask the doctor. I am a 50-year-old man with congestive heart failure. My doctor has me on all the usual drugs, and a couple of years ago added spironolactone. I did okay with it for a while, but then began to notice that my breasts were getting bigger and began to hurt. My doctor agreed that I should stop taking spironolactone, but I wonder if I am missing out on something. Lee TH Harv Heart Lett; 2003 Oct; 14(2):8. PubMed ID: 14576040 [No Abstract] [Full Text] [Related]
12. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites]. Traina M; Vizzini GB Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409 [TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of spironolactone-induced gynecomastia. Rose LI; Underwood RH; Newmark SR; Kisch ES; Williams GH Ann Intern Med; 1977 Oct; 87(4):398-403. PubMed ID: 907238 [TBL] [Abstract][Full Text] [Related]
15. Unilateral gynecomastia and impotence during low-dose spironolactone administration in men. Zarren HS; Black PM Mil Med; 1975 Jun; 140(6):417-9. PubMed ID: 807887 [No Abstract] [Full Text] [Related]
16. Spironolactone-induced bilateral gynecomastia in a man detected by SPECT myocardial perfusion imaging. Farag AA; Andrikopoulou E; Hage FG J Nucl Cardiol; 2017 Apr; 24(2):742. PubMed ID: 27151301 [No Abstract] [Full Text] [Related]
17. [Controlled clinical trial for the comparison of tolerance of two aldosterone antagonists]. Leizorovicz A; Guenaneche F; Luciani J; Boissel JP Therapie; 1991; 46(4):327-31. PubMed ID: 1948810 [TBL] [Abstract][Full Text] [Related]
18. [Iatrogenic gynecomastia in aldosterone-antagonist therapy]. Quietzsch D Z Gesamte Inn Med; 1981 Feb; 36(3):87-9. PubMed ID: 7222857 [TBL] [Abstract][Full Text] [Related]